Tag: neurodegenerative disorder therapeutics market forecast

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Neurodegenerative Disorder Therapeutics Market From 2026 To 2030?

The neurodegenerative disorder therapeutics market size has shown robust growth in recent years. It is anticipated to expand from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth can be ascribed to several factors, including the increasing incidence of neurodegenerative disorders, a growing elderly population, restricted availability of treatment options, greater awareness leading to early diagnosis, and enhancements in hospital and neurology care infrastructure.

The neurodegenerative disorder therapeutics market size is anticipated to experience robust expansion in the coming years. It is forecast to achieve a value of $34.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This projected growth throughout the forecast period stems from factors such as the development of gene therapies, advancements in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Prominent trends for the forecast period include the rising adoption of neuroprotective and neurorestorative therapies, a greater focus on symptom management and patient-centric care, an increase in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the integration of home care and remote monitoring solutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What Key Drivers Are Influencing The Growth Of The Neurodegenerative Disorder Therapeutics Market?

Heightened investment in research and development (R&D) for neurodegenerative disorder therapeutics is expected to propel the growth of the neurodegenerative disorder therapeutics market moving forward. Governments and organizations initiate investments in research and development for neurodegenerative disorders for various compelling reasons, including their increasing prevalence, significant unmet medical needs, economic repercussions, global health initiatives, and more. For instance, in March 2023, according to Government of Canada, a Canada-based federal administration, the government of Canada revealed a $38.3 million investment in 2023 aimed at advancing research into neurodegenerative diseases. Therefore, increasing investment in research and development (R&D) for neurodegenerative disorder therapeutics will continue to drive the growth of the neurodegenerative disorder therapeutics market in the forecast period.

Which Segments Are Included In The Analysis Of The Neurodegenerative Disorder Therapeutics Market?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Which Trends Are Impacting The Growth Of The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are focusing on developing innovative treatment options, such as prodrug formulations, to enhance the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically converted into active drugs in the body, allowing for controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for people living with advanced Parkinson’s disease. The therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and improve patients’ quality of life. This launch represents a significant advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.

Which Key Industry Participants Are Active In The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Read the full neurodegenerative disorder therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Neurodegenerative Disorder Therapeutics Market?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurodegenerative Disorder Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company

Neurology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neurosurgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the neurodegenerative disorder therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Neurodegenerative Disorder Therapeutics Market?

The neurodegenerative disorder therapeutics market size has experienced robust expansion over the past few years. This market is projected to expand from $21.66 billion in 2025 to $23.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. Historically, this growth has been driven by factors such as the increasing prevalence of neurodegenerative disorders, a burgeoning aging population, the presence of limited treatment options, heightened awareness regarding early diagnosis, and the development of hospital and neurology care infrastructure.

The neurodegenerative disorder therapeutics market is poised for substantial expansion in the coming years. This market is projected to reach $34.13 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period is attributable to the development of gene therapies, progress in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Significant trends over the forecast period are expected to include the increasing adoption of neuroprotective and neurorestorative therapies, a heightened focus on symptom management and patient-centric care, a rise in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the incorporation of home care and remote monitoring solutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What Drivers Are Supporting Technological Adoption In The Neurodegenerative Disorder Therapeutics Market?

Enhanced financial commitment to research and development (R&D) for neurodegenerative disorder treatments is projected to fuel the expansion of the neurodegenerative disorder therapeutics market in the future. Governments and various organizations initiate these R&D investments in neurodegenerative disorders due to several pressing factors, such as the rising incidence, considerable unmet healthcare demands, economic impacts, and worldwide health endeavors, among others. For instance, in March 2023, the Government of Canada, a Canada-based federal administration, disclosed a $38.3 million investment in 2023, dedicated to boosting research into neurodegenerative diseases. Consequently, sustained investment in R&D for neurodegenerative disorder therapeutics is anticipated to continuously spur the growth of the neurodegenerative disorder therapeutics market throughout the forecast timeframe.

Which Segments Are Contributing To The Growth Of The Neurodegenerative Disorder Therapeutics Market?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Which Trends Are Expected To Influence The Neurodegenerative Disorder Therapeutics Market In The Upcoming Years?

Major companies in the neurodegenerative disorder therapeutics market are concentrating on developing innovative treatment options, particularly prodrug formulations, to enhance the bioavailability, efficacy, and safety profiles of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically transformed into active drugs within the body, enabling controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to diminish motor fluctuations and improve patients’ quality of life. This launch represents a significant advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.

Who Are The Major Companies Operating In The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Neurodegenerative Disorder Therapeutics Market?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurodegenerative Disorder Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company

Neurology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neurosurgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Neurodegenerative Disorder Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?

The market for therapeutics for neurodegenerative disorders has seen a robust growth recently. It is predicted to expand from $18.53 billion in 2024 to $20.04 billion in 2025, progressing at a compound annual growth rate (CAGR) of 8.1%. The past growth in the market can be traced back to factors like an increasing aging population, a higher occurrence of neurodegenerative disorders, increased life expectancy, greater investments from pharmaceutical firms, and heightened awareness and advocacy initiatives.

What Is the Forecast for the Neurodegenerative Disorder Therapeutics Market Size Through 2029?

The market for therapeutic solutions for neurodegenerative disorders is forecasted to experience substantial growth in the coming years. The market is projected to reach a value of $28.33 billion by 2029, achieving a Compound Annual Growth Rate (CAGR) of 9.0%. This growth is set to be fueled by a number of factors such as the increasing demand for personalized and targeted therapies, the widespread availability of clinical trials, and an overall increase in healthcare expenditure. Notable developments predicted for this period include therapies that modify the course of the disease, non-drug-based interventions, the use of telemedicine and remote monitoring, technological advancements, precision therapies, digital health initiatives, and trials centered around specific biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What are the Key Market Players in Neurodegenerative Disorder Therapeutics Market and How They’re Evolving?

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

What Are the Primary Growth Drivers in the Neurodegenerative Disorder Therapeutics Market?

The growth of the neurodegenerative disorder therapeutics market is being fuelled by a rising incidence of neurodegenerative disorders among the global populace. This increase is driven in part by the rise in the elderly population, which has a higher occurrence of these conditions. As per the World Population Prospects data, by 2024, we are looking at a jump in individuals over 60 years old to 2.1 billion by 2050, while those over the age of 80 will have grown threefold to 425 million. Furthermore, figures from the Alzheimer’s Association reveal that nearly 5.8 million US citizens are battling Alzheimer’s disease, with the forecast indicating a surge to approximately 14 million by 2050. Hence, with an escalating occurrence of neurodegenerative diseases in the older demographic, the need for neurodegenerative disorder therapeutics amplifies, prompting the progression of the market in this field.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp

What Are the Leading Segments in the Global Neurodegenerative Disorder Therapeutics Industry?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

What Are the Key Market Trends in the Neurodegenerative Disorder Therapeutics Industry?

Firms dealing with therapeutic treatments for neurodegenerative disorders are forming various strategic alliances with both governmental and non-governmental entities in order to explore and establish new therapies for an array of neurodegenerative diseases. There is also a rise in cooperation among participants in the neurodegenerative disorders therapeutics sector to amplify their research and development capabilities, with a focus on creating innovative and more successful treatment options. In a specific example from July 2022, NRG Therapeutics, a UK-based company that specialises in therapeutic solutions, collaborated with Domainex, a UK-based drug discovery service. The aim of their partnership is to collectively develop unique small-molecule disease-altering medications that can effectively treat Parkinson’s disease, motor neuron disease (MND) and other severe chronic neurodegenerative conditions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

What Is the Regional Outlook for the Neurodegenerative Disorder Therapeutics Market?

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818

This Report Delivers Insight On:

1. How big is the neurodegenerative disorder therapeutics market, and how is it changing globally?

2. Who are the major companies in the neurodegenerative disorder therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the neurodegenerative disorder therapeutics market right now?

4. Which products or customer segments are growing the most in the neurodegenerative disorder therapeutics market?

5. What factors are helping or slowing down the growth of the neurodegenerative disorder therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the neurodegenerative disorder therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has The Neurodegenerative Disorder Therapeutics Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

In recent years, the market size for therapeutics for neurodegenerative disorders has experienced significant growth. It is set to expand from $18.53 billion in 2024 to $20.04 billion in 2025, marking a compound annual growth rate (CAGR) of 8.1%. Factors that have contributed to the growth in the historic period include an aging population, an increase in cases of neurodegenerative disorders, longer life expectancy, heightened investments by pharmaceutical companies, and a rise in awareness and advocacy._x000D_

_x000D_

In the upcoming years, the neurodegenerative disorder therapeutics market is anticipated to witness robust growth, with its projected value reaching $28.33 billion in 2029, at a compound annual growth rate (CAGR) of 9.0%. Factors influencing this growth over the forecast period include the surge in demand for targeted therapy and personalized medicine, the increasing number of clinical trials, and escalating healthcare spending. Key trends during this forecast period encompass disease-altering treatments, non-drug interventions, telemedicine, and remote monitoring practices, breakthroughs in technology, precision treatments, digital healthcare solutions, and trials driven by biomarkers._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp_x000D_

_x000D_

#What Are the Core Growth Drivers Propelling the Neurodegenerative Disorder Therapeutics Market Forward?#_x000D_

The rising occurrences of neurodegenerative ailments globally are fueling the growth of the market for neurodegenerative disorder treatments. The rise in elderly population is linked to a higher incidence of these disorders. For instance, data from the World Population Prospects in 2024 suggest that the population aged above 60 years will reach 2.1 billion by 2050, with those aged over 80 years almost tripling to 425 million. As per the Alzheimer’s Association, nearly 5.8 million Americans currently have Alzheimer’s disease, and this figure is expected to increase to approximately 14 million by 2050. The elevated occurrence of neurodegenerative diseases in the aging demographic accentuates the need for therapeutics for neurodegenerative disorders, thus stimulating the market for these treatments._x000D_

_x000D_

#What Segment Types Define the Neurodegenerative Disorder Therapeutics Market Structure?#_x000D_

The neurodegenerative disorder therapeutics market covered in this report is segmented –_x000D_

_x000D_

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types_x000D_

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types_x000D_

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics_x000D_

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies_x000D_

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids_x000D_

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications_x000D_

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Neurodegenerative Disorder Therapeutics Market?#_x000D_

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada._x000D_

_x000D_

#What Long-Term Trends Are Transforming the Competitive Landscape of the Neurodegenerative Disorder Therapeutics Market?#_x000D_

Producers of therapeutics for neurodegenerative disorders are entering into strategic partnerships with both governmental and non-governmental organizations to research and develop treatments for a wide array of neurodegenerative diseases. They are also enhancing their collaboration with other market participants to augment their research and development capabilities, with the aim of creating newer, more effective therapies for neurodegenerative disorders. For instance, NRG Therapeutics, a UK-based company that specializes in therapeutic solutions, announced a partnership with Domainex, a UK-based drug discovery service, in July 2022 to develop treatments for neurodegenerative disorders. Their collaboration would focus on creating innovative small-molecule disease-altering medications intended for the treatment of Parkinson’s disease, motor neuron disease (MND), among other debilitating ongoing neurodegenerative conditions._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report_x000D_

_x000D_

#What Is the Definition of the Neurodegenerative Disorder Therapeutics Market?#_x000D_

Neurodegenerative disorder therapeutics refers to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theLeqembi Market?

The growing prevalence of Alzheimer’s disease is expected to propel the growth of the Leqembi market. Alzheimer’s disease is a degenerative brain disorder that affects memory, cognition, and behavior. Leqembi reduces beta-amyloid plaques in the brain, helping slow cognitive decline in early Alzheimer’s patients. For instance, in September 2024, the European Brain Council reported that approximately 7 million people in Europe live with Alzheimer’s disease, with the number expected to double by 2030. Therefore, the increasing prevalence of Alzheimer’s disease is driving the growth of the Leqembi market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20142&type=smp

#What Growth Opportunities Will Drive the Leqembi Market’s CAGR Through 2034?

The leqembi market size has XX (HCAGR) in recent years. It is expected to rise from $XX million in 2024 to $XX million in 2025 at a CAGR of XX%. Growth was driven by a larger elderly population, more funding for neurodegenerative disease research, improved reimbursement, promising clinical trial data, and increased healthcare spending.

The leqembi market size is expected to grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The forecasted growth is attributed to increased R&D spending, rising awareness of Alzheimer’s early diagnosis, the global prevalence of Alzheimer’s disease, demand for neurodegenerative disorder treatments, and a focus on amyloid plaque reduction. Key trends include advancements in neuroscience R&D, digital health technologies, personalized medicine, and disease-modifying therapies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20142

Who Are the Major Industry Players Accelerating Growth in theLeqembi Market?

Major companies operating in the leqembi market include Eisai Co. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Which Primary Segments of the Leqembi Market Are Driving Growth and Industry Transformations?

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

3) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20142&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theLeqembi Market?# Market?

North America was the largest region in the leqembi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Leqembi Market 2025, By The Business Research Company:

Alzheimer’s Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Alzheimer’s Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Lewy Body Dementia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theNeurodegenerative Disorder Therapeutics Market from 2025 to 2034?

The increasing prevalence of neurodegenerative diseases, particularly among the aging population, is driving the growth of the neurodegenerative disorder therapeutics market. The number of people over 60 is expected to reach 2.1 billion by 2050, with a significant increase in those aged 80 and above. For instance, in 2024, the Alzheimer’s Association estimated that 5.8 million Americans suffer from Alzheimer’s disease, with numbers expected to rise to 14 million by 2050. This rising prevalence is fueling demand for treatments, thereby propelling the neurodegenerative disorder therapeutics market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

#What Long-Term Growth Rate is Expected for theNeurodegenerative Disorder Therapeutics Market Between 2025 and 2034?

The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $18.53 billion in 2024 to $20.04 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. Growth is driven by an aging population, rising prevalence of neurodegenerative disorders, increasing life expectancy, and greater investments from pharmaceutical companies in research.

The neurodegenerative disorder therapeutics market is expected to grow strongly, reaching $28.33 billion by 2029, with a CAGR of 9.0%. The growth is attributed to rising demand for personalized medicine, targeted therapies, increasing clinical trial availability, and growing healthcare expenditure. Major trends include disease-modifying therapies, non-pharmacological interventions, digital health solutions, and biomarker-driven trials.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818

Which Upcoming Market Trends and Innovations Are Set to Influence theNeurodegenerative Disorder Therapeutics Market’s Path Forward?

Companies in the neurodegenerative disorder therapeutics market are forming strategic alliances to accelerate the development of treatments for diseases like Parkinson’s and motor neuron disease. For example, NRG Therapeutics partnered with Domainex in July 2022 to create novel small-molecule medications for these conditions.

Which Key Market Players Are Shaping the Future and Growth of theNeurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

What Are the Core Segments of the Neurodegenerative Disorder Therapeutics Market, and How Do They Contribute to Growth?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp

What Regions Are Dominating the Neurodegenerative Disorder Therapeutics Market Growth?

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2025, By The Business Research Company:

Neurosurgery Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Neurology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Brain And Neuroimaging Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the neurodegenerative disorder therapeutics market grown over the years?

In recent times, there has been significant growth in the market size for therapeutics related to neurodegenerative disorders. The projected growth is from $18.53 billion in 2024 to $20.04 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.1%. Various factors such as an aging population, increased occurrence of neurodegenerative disorders, amplified life expectancy, enhanced investments by pharmaceutical companies, awareness, and advocacy have contributed to this growth seen in the historical period.

What Is the forecasted market size and growth rate for the neurodegenerative disorder therapeutics market?

Anticipated expansion is strong for the neurodegenerative disorder therapeutics market, which is projected to surge to $28.33 billion by 2029, with a compound annual growth rate (CAGR) of 9.0%. The growth within this prediction horizon is due to the increasing demand for personalized medicine, targeted therapy, an uplift in the availability of clinical trials, and upsurging healthcare spending. Some of the key trends for the forecast period would be disease-modifying treatments, non-drug interventions, telemedicine and remote patient monitoring, advancements in technology, precision therapeutics, digital health approaches, and biomarker-dependent trials.

Get your neurodegenerative disorder therapeutics market report here!

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What are the major factors driving growth in the neurodegenerative disorder therapeutics market?

The rising incidence of neurodegenerative diseases worldwide is positively contributing to the growth of the neurodegenerative disorder therapeutics market. The surge in the elderly population is linked to the heightened occurrence of these disorders. For example, by 2024, World Population Prospects forecasts that individuals over 60 will reach 2.1 billion by 2050 and those over 80 are expected to triple to 425 million by 2050. The Alzheimer’s Association states that approximately 5.8 million Americans currently suffer from Alzheimer’s disease, and that figure is anticipated to increase to about 14 million by 2050. The rising cases of neurodegenerative diseases in the elderly demographic boosts the demand for therapeutics for these disorders, which in turn is propelling the growth of the neurodegenerative disorder therapeutics market.

What key areas define the segmentation of the global neurodegenerative disorder therapeutics Market?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What are the top market players propelling the growth of the neurodegenerative disorder therapeutics industry?

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

What are the key trends shaping the future of the neurodegenerative disorder therapeutics market?

Companies manufacturing therapeutics for neurodegenerative ailments are actively engaging in strategic alliances with governmental and non-governmental bodies to expand the discovery and development of treatments for multiple neurodegenerative conditions. Market players in the neurodegenerative disorder therapeutics sector are amplifying their collaborations in an effort to enhance their research and development capacities. This is done with the intention to create novel and more potent therapeutic solutions for neurodegenerative disorders. To illustrate, in July 2022, UK’s NRG Therapeutics, a firm committed to devising therapeutic strategies, teamed up with another UK firm, Domainex, a leading player in drug discovery services, with the aim to construct treatments for neurodegenerative diseases. The collaboration intends to concoct new disease-modifying medicines in the form of small molecules, targeting debilitating chronic neurodegenerative diseases like Parkinson’s disease and motor neuron disease (MND).

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818

What regions are dominating the neurodegenerative disorder therapeutics market growth?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Neurosurgery Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Neurology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Brain And Neuroimaging Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: